Status:

COMPLETED

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Lead Sponsor:

Santen Pharmaceutical (Taiwan) Co., LTD

Conditions:

Ocular Surface Disease

Primary Open Angle Glaucoma

Eligibility:

All Genders

20+ years

Brief Summary

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline t...

Detailed Description

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline t...

Eligibility Criteria

Inclusion

  • Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to extraction of data according to the protocol)
  • According to the approved indications of Tafluprost / Timolol as indicated in the SPC
  • Male or female patients ≥20 years of age at time of informed consent
  • Diagnosis of open angle glaucoma or ocular hypertension
  • Insufficient IOP control with a monotherapy utilizing topical prostaglandin analogues, necessitating the use of a combination therapy according to the judgement of the treating ophthalmologist
  • Patient judged by their physician to benefit from preservative free eye drops
  • Not used Tafluprost / Timolol before

Exclusion

  • Patient pregnant or nursing
  • Pregnancy planned in the following 6 months
  • Presence of contraindications as listed in the SPC
  • Any ophthalmologic surgery within 6 months prior to the study
  • Participation in any other investigational study within 30 days prior to enrolment

Key Trial Info

Start Date :

September 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 24 2022

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04828057

Start Date

September 1 2021

End Date

August 24 2022

Last Update

October 31 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital

Taoyuan, Taiwan, 333012